(Q37921797)

English

Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?

scientific article published on 25 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look? (English)

1 reference

Europe PubMed Central

25 August 2017

0 references

author name string

David Bruce

1

1 reference

Europe PubMed Central

25 August 2017

Peng H Tan

2

1 reference

Europe PubMed Central

25 August 2017

language of work or name

0 references

publication date

25 August 2011

1 reference

Europe PubMed Central

25 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

25 August 2017

20

1 reference

Europe PubMed Central

25 August 2017

1413-1434

1 reference

Europe PubMed Central

25 August 2017

10

1 reference

Europe PubMed Central

25 August 2017

VEGF receptor signalling - in control of vascular function

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

An overview of small-molecule inhibitors of VEGFR signaling

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

The role of the VEGF-C/VEGFR-3 axis in cancer progression

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Mechanisms of resistance to antiangiogenesis therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Tyrphostins and other tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Targeting cancer with small molecule kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Mechanisms of drug inhibition of signalling molecules

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Targeting vascular endothelial growth factor in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

BIBF 1120 for the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Non-viral delivery of ribozymes for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Bevacizumab resistance in breast cancer: are neuropilins the key?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Current insights on the biology and clinical aspects of VEGF regulation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611801

21 January 2018

Identifiers

10.1517/13543784.2011.611801

1 reference

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37921797&oldid=1557108145"